A Phase I and Randomized, Double-Blinded Phase II Study of Nab-Paclitaxel/Gemcitabine Plus AZD1775 or Placebo in Treatment-Naive Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Phase I and Randomized, Double-Blinded Phase II Study of Nab-Paclitaxel/Gemcitabine Plus AZD1775 or Placebo in Treatment-Naive Metastatic Adenocarcinoma of the Pancreas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 Status changed from suspended to active, no longer recruiting.
    • 13 Jan 2017 Status changed from recruiting to suspended for assessment.
    • 26 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top